Lilly Doubles Down on Nimbus in $1.3B Oral Obesity Pact
Nimbus Therapeutics has entered into a multi-year research collaboration and exclusive worldwide license agreement with Eli Lilly and Company to
Read moreNimbus Therapeutics has entered into a multi-year research collaboration and exclusive worldwide license agreement with Eli Lilly and Company to
Read moreSanofi has announced it has agreed to acquire Dynavax Technologies Corporation, a publicly traded vaccines company, in a move that
Read moreNovo Nordisk A/S has announced that the US Food and Drug Administration (FDA) has approved the Wegovy® pill (once-daily oral
Read moreThe new Huntsville, Alabama site will produce small molecule and peptide medicines, including oral GLP-1 orforglipron Eli Lilly and Company
Read moreStriatech is pleased to announce its next Journal Club: Gene-Agnostic Gene Therapy to Preserve Vision, which will be held on
Read moreMerck & Co., Inc. announced on Monday a sweeping expansion of its U.S. operations, pledging more than $70 Billion in
Read morePfizer Inc. has reached a sweeping agreement with the Trump Administration that will reduce prescription drug costs for U.S. patients
Read moreAstraZeneca, the Anglo-Swedish pharmaceutical giant, announced on Monday, plans to harmonise its share listing structure across the London Stock Exchange
Read moreThe definitive merger agreement, valued at up to $3.5 billion, grants Roche control of the late-stage FGF21 analog, pegozafermin, for
Read moreMerck & Co., known as MSD outside of the United States and Canada, announced on Saturday that the U.S. Food
Read more